{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-26-000054","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.602738+00:00","generated_at":"2026-05-15T09:00:05.107213+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Recursion appoints Vicki Goodman as CMO effective April 6, 2026; David Mauro transitions out","bullets":["Dr. Goodman joins from Mural Oncology as CMO; prior executive roles at Exelixis, Merck, BMS, and GSK.","Outgoing CMO Dr. Mauro will serve as advisor until May 29, 2026, after three years at Recursion.","CEO Najat Khan highlights Goodman's late-stage clinical development experience for advancing pipeline.","Company reiterates key clinical and regulatory milestones consistent with prior expectations."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-26-000054","json":"https://secwatch.observer/filing/0001601830-26-000054.json","markdown":"https://secwatch.observer/filing/0001601830-26-000054.md","text":"https://secwatch.observer/filing/0001601830-26-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000054/0001601830-26-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000054/rxrx-20260325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:00:05.107213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}